GE Healthcare beats Q3 revenue estimates on strong US, EMEA demand

GE HealthCare Technologies

29/10/2025 10:28

Overview

GE Healthcare Q3 revenue grows 6% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, despite tariff impacts

Company raises lower end of full-year 2025 Adjusted EPS guidance

Outlook

GE HealthCare raises lower end of full-year 2025 Adjusted EPS guidance to $4.51-$4.63

Company expects 2025 organic revenue growth of approximately 3% year-over-year

GE HealthCare anticipates 2025 free cash flow of at least $1.4 bln

Result Drivers

REGIONAL PERFORMANCE - Revenue growth driven by strong demand in EMEA and US

SEGMENT CONTRIBUTION - Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics led revenue performance

TARIFF IMPACTS - Tariffs affected margins and EPS, partially offset by volume and price benefits

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$5.10 bln
$5.08 bln (13 Analysts)
Q3 Adjusted EPS
Beat
$1.07
$1.05 (13 Analysts)
Q3 EPS
$0.98
Q3 Net Income
$446 mln
Q3 Adjusted Free Cash Flow
$593 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for GE Healthcare Technologies Inc is $88.00, about 9.8% above its October 28 closing price of $79.40

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw29ckRna

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)